Takeda (TAK) HR chief Greenway sells 34,603 ADS in August 2026 trades

Rhea-AI Filing Summary

Takeda Pharmaceutical Co Ltd officer Nicola Deidre Petal Greenway, Chief Human Resources Officer, reported selling a total of 34,603 American Depositary Shares of Takeda on 2026-08-10. The sales were reported as open-market or private transactions at prices around $17.50 per ADS, with direct ownership status.

Insider Trade Summary

Net Seller: 34,603 shares

Net Sell 2 txns

Insider Greenway Nicola Deidre Petal

Role Chief Human Resources Officer

Sold 34,603 shs ($606K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares	975	$17.50	$17K
Sale	American Depositary Shares	33,628	$17.5067	$589K

Holdings After Transaction: American Depositary Shares — 59,803 shares (Direct)

Key Figures

Shares sold (block 1): 975 American Depositary Shares Shares sold (block 2): 33,628 American Depositary Shares Total shares sold: 34,603 American Depositary Shares +2 more

5 metrics

Shares sold (block 1) 975 American Depositary Shares Sale on 2026-08-10 at $17.5000 per share

Shares sold (block 2) 33,628 American Depositary Shares Sale on 2026-08-10 at $17.5067 per share

Total shares sold 34,603 American Depositary Shares Aggregate of reported sales by Nicola Greenway on 2026-08-10

Sale price (block 1) $17.5000 per share American Depositary Shares sold directly by Nicola Greenway

Sale price (block 2) $17.5067 per share American Depositary Shares sold directly by Nicola Greenway

Key Terms

American Depositary Shares, open market or private transaction, Rule 10b5-1

3 terms

American Depositary Shares financial

"security_title: "American Depositary Shares" for each transaction"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

open market or private transaction financial

"transaction_code_description: "Sale in open market or private transaction""

Rule 10b5-1 regulatory

"aff_10b5_one indicates Rule 10b5-1 trading plan checkbox status"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What insider transaction did Takeda (TAK) report for Nicola Greenway?

Takeda reported that Chief Human Resources Officer Nicola Deidre Petal Greenway sold a total of 34,603 American Depositary Shares on 2026-08-10 in open-market or private transactions at prices around $17.50 per share.

How many Takeda (TAK) ADS did Nicola Greenway sell and at what prices?

Nicola Greenway sold 975 ADS at $17.5000 and 33,628 ADS at $17.5067. All reported trades involved American Depositary Shares of Takeda and were classified as open-market or private sale transactions.

What is Nicola Greenway’s role at Takeda (TAK) in this Form 4 filing?

In this Form 4, Nicola Deidre Petal Greenway is identified as an officer of Takeda, serving as Chief Human Resources Officer. The reported transactions involve her direct ownership of Takeda American Depositary Shares.

Were Nicola Greenway’s Takeda (TAK) share sales under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirming a trading plan, and no footnotes describe a plan. The sales are reported simply as open-market or private transactions in Takeda American Depositary Shares.

What type of security did Nicola Greenway trade in Takeda (TAK)?

All reported transactions involve American Depositary Shares of Takeda Pharmaceutical Co Ltd. These ADS trades on 2026-08-10 were recorded as sales in open-market or private transactions at approximately $17.50 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 04:10 PM Accepted by SEC EDGAR 08/12/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Greenway Nicola Deidre Petal

(Last) (First) (Middle)

500 KENDALL STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	08/10/2026		S		975	D	$17.5	93,431	D
American Depositary Shares	08/10/2026		S		33,628	D	$17.5067	59,803	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Samuel Ntonme, by power of attorney, for Nicola D. Greenway	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)